DHMB

CAS No. 4055-69-0

DHMB ( 2,3-Dihydroxy-4-Methoxybenzaldehyde )

Catalog No. M27382 CAS No. 4055-69-0

DHMB exerts protective effects on intestinal epithelial cells. DHMB exhibits anti-inflammatory and antifungal capacity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 393 In Stock
10MG 581 In Stock
25MG 888 In Stock
50MG 1242 In Stock
100MG 1674 In Stock
500MG 3348 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    DHMB
  • Note
    Research use only, not for human use.
  • Brief Description
    DHMB exerts protective effects on intestinal epithelial cells. DHMB exhibits anti-inflammatory and antifungal capacity.
  • Description
    DHMB exerts protective effects on intestinal epithelial cells. DHMB exhibits anti-inflammatory and antifungal capacity.
  • Synonyms
    2,3-Dihydroxy-4-Methoxybenzaldehyde
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Apoptosis
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    4055-69-0
  • Formula Weight
    168.1
  • Molecular Formula
    C8H8O4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    COc1ccc(C=O)c(O)c1O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Kim T, Kim YJ, Han IH, Lee D, Ham J, Kang KS, Lee JW. The synthesis of sulforaphane analogues and their protection effect against cisplatin induced cytotoxicity in kidney cells. Bioorg Med Chem Lett. 2015 Jan 1;25(1):62-6. doi: 10.1016/j.bmcl.2014.11.014. Epub 2014 Nov 11. PMID: 25466193.
molnova catalog
related products
  • SJ6986

    SJ6986 is a chemical probe for studying the role of GSPT1/2 in vitro and in vivo. SJ6986 supports the utility of a diverse library of CRBN binders in the pursuit of targeting undruggable oncoproteins.

  • Patrinia saponin H3

    The herbs of Lonicera japonica Thunb.

  • AM966

    AM966, a excellent affinity, specific, oral LPA1(IC50=17 nM) antagonist, suppresses LPA-stimulated intracellular calcium release.